Atamestane
- Generic Name
- Atamestane
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H26O2
- CAS Number
- 96301-34-7
- Unique Ingredient Identifier
- 62GA3K28B6
- Background
Atamestane has been used in trials studying the treatment of Breast Cancer, Breast Neoplasms, and Neoplasms, Hormone-Dependent.
- Associated Conditions
- -
- Associated Therapies
- -
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
- Conditions
- First Posted Date
- 2005-12-21
- Last Posted Date
- 2007-09-10
- Lead Sponsor
- Intarcia Therapeutics
- Target Recruit Count
- 200
- Registration Number
- NCT00267553
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
- Conditions
- First Posted Date
- 2004-11-23
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Intarcia Therapeutics
- Target Recruit Count
- 842
- Registration Number
- NCT00097344
- Locations
- 🇺🇦
Research Site, Vinnitsa, Ukraine
🇷🇺Research site, Krasnodar, Russian Federation
Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-05-05
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Intarcia Therapeutics
- Registration Number
- NCT00010322
- Locations
- 🇺🇸
Millennix Inc., Purchase, New York, United States
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
- First Posted Date
- 2002-08-27
- Last Posted Date
- 2015-07-31
- Lead Sponsor
- Intarcia Therapeutics
- Target Recruit Count
- 865
- Registration Number
- NCT00044291
- Locations
- 🇺🇦
Kharkov Medical Academy of Postgraduate Education, Oncology and Pediatric Oncology Department. Clinical Facility: Kharkov Regional Clinical Oncology Dispensary, Chemotherapy Department, Kharkov, Ukraine
🇺🇦Odessa State Medical University, Oncology Department. Clinical Facility: Odessa Regional Oncology Center, Chemotherapy Department, Odessa, Ukraine
🇷🇺V. Novgorod Regional Oncology Center, Department of Chemotherapy, V. Novgorod, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.